Inhibikase Therapeutics Stock (NASDAQ:IKT)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$2.53

52W Range

$0.80 - $3.82

50D Avg

$1.56

200D Avg

$1.78

Market Cap

$177.39M

Avg Vol (3M)

$421.65K

Beta

1.33

Div Yield

-

IKT Company Profile


Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

8

IPO Date

Dec 23, 2020

Website

IKT Performance


IKT Financial Summary


Dec 23Dec 22Dec 21
Revenue$260.50K$123.44K$3.10M
Operating Income$-20.09M$-18.13M$-14.77M
Net Income$-19.03M$-17.91M$-14.81M
EBITDA$-19.91M$-18.12M$-14.77M
Basic EPS$-3.57$-4.26$-4.88
Diluted EPS$-3.57$-4.26$-4.88

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 15, 24 | 6:13 PM
Q1 24May 17, 24 | 9:57 PM
Q4 23Mar 28, 24 | 5:13 PM

Peer Comparison


TickerCompany
SIOXSio Gene Therapies Inc.
PMVPPMV Pharmaceuticals, Inc.
NTRBNutriband Inc.
SCPHscPharmaceuticals Inc.
LGVNLongeveron Inc.
QNRXQuoin Pharmaceuticals, Ltd.
MCRBSeres Therapeutics, Inc.
ANTXAN2 Therapeutics, Inc.
VRAXVirax Biolabs Group Limited
ONCYOncolytics Biotech Inc.
RNXTRenovoRx, Inc.
DMACDiaMedica Therapeutics Inc.
TPSTTempest Therapeutics, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
MISTMilestone Pharmaceuticals Inc.
LIFEaTyr Pharma, Inc.